RE:RE:RE:RE:Thanks West ---the Bull Case -Unoteable??Basic research by anyone would show that Oncorus is a Phase 1 early stage OV company with a intratumorally (IT) administered HSV in melanoma, which is a crowded indication to try to develop an OV candidate. Furthermore, their pipeline is still in the pre-clinical stage with any potential IV administered OV products, which were decided on development in May 2021, using the Coxsckievirus and Seneca virus - both already in development by other OV companies.
https://oncorus.com/pipeline/
In contrast ONCY is a late stage OV company currently completing the enfollment of their Phase 2 BRACELET study in metastatic Breast Cancer with the intravenously (IV) administered patent protected/proprietary oncolytic virus (OV) pelareorep . The mBC BRACELET study is the pre-cursor to ONCY's biomarker driven and partner sponsored Phase 3 registration study in patients with HR+/HER2 negative mBC - which had showed a double of overall survival (OS) in ONCY's IND-213 study, and which in turn prompted the AWARE-1 and now the BRACELET-1 studies.